The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | ICML 2017 Highlights
George Follows, MA, PhD, MRCP, FRCPath from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses ICML 2017 highlights at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. The German Hodgkin Study Data Group showed patients treated with escalated BEACOPP chemotherapy had improved outcomes (NCT01569204), however, the RATHL study (NCT01304849) showed that de-escalation of treatment in PET negative patients doesn’t compromise their outcome. CAR T-cell therapy is also an exciting field, particularly in the treatment of relapsed high-grade lymphomas, with 50% of patients treated in complete remission. Prof. Follows states that in comparison to America, Europe are behind in using these new treatments, however, this will hopefully improve soon.
